Free tool
FAERS Monitor: Humalog Mix 50/50 Kwikpen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021018 or its brand name (Humalog Mix 50/50 Kwikpen, Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant). Reports on generic versions are filed under their own applications.
Reports
123,775
Serious
59,244
48% of reports
Hospitalization
31,930
Death reported
5,612
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased34,684
- blood glucose decreased8,066
- incorrect dose administered7,997
- drug ineffective7,527
- visual impairment4,804
- nausea4,696
- malaise3,657
- hypoglycaemia3,632
- fatigue3,581
- fall3,258
- drug dose omission3,241
- vomiting3,118
- diarrhoea3,094
- dyspnoea2,970
- pain2,959
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,188 |
| 2005 | 1,265 |
| 2006 | 1,680 |
| 2007 | 1,554 |
| 2008 | 1,463 |
| 2009 | 1,792 |
| 2010 | 1,836 |
| 2011 | 2,030 |
| 2012 | 2,096 |
| 2013 | 1,703 |
| 2014 | 4,546 |
| 2015 | 24,696 |
| 2016 | 8,366 |
| 2017 | 8,084 |
| 2018 | 8,473 |
| 2019 | 8,512 |
| 2020 | 8,710 |
| 2021 | 7,308 |
| 2022 | 6,399 |
| 2023 | 5,579 |
| 2024 | 5,212 |
| 2025 | 7,616 |
| 2026 | 3,667 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,930,384 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood glucose increasedSignal | 34,684 | 38.1 | 37.7 | 1,031,947 |
| blood glucose decreasedSignal | 8,066 | 34.1 | 33.3 | 216,111 |
| hypoglycaemiaSignal | 3,632 | 13.7 | 13.2 | 39,549 |
| visual impairmentSignal | 4,804 | 6.8 | 6.6 | 23,033 |
| incorrect dose administeredSignal | 7,997 | 6.1 | 6.0 | 33,511 |
| drug dose omissionSignal | 3,241 | 3.4 | 3.3 | 5,360 |
| fall | 3,258 | 1.7 | 1.6 | 880 |
| malaise | 3,657 | 1.4 | 1.4 | 460 |
| vomiting | 3,118 | 1.1 | 1.1 | 46 |
| nausea | 4,696 | 1.0 | 1.0 | 0 |
| drug ineffective | 7,527 | 1.0 | 0.9 | 7 |
| dyspnoea | 2,970 | 0.9 | 0.9 | 40 |
| pain | 2,959 | 0.8 | 0.8 | 123 |
| diarrhoea | 3,094 | 0.8 | 0.8 | 135 |
| fatigue | 3,581 | 0.8 | 0.8 | 228 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.